Cut Complexity, Not Corners: Reducing Cost Drivers And Improving Efficiency In CAR T Cell Manufacturing

In CAR T cell therapy, the gap between clinical promise and patient access is shaped, in part, by manufacturing economics. Modular workflows, which typically require separate instruments for each process step, carry compounding costs: personnel can represent up to a quarter of total manufacturing expenses, each operator intervention introduces deviation risk estimated at roughly 10 hours of remediation per event, and class B cleanroom requirements add infrastructure overhead that scales poorly. This case study presents a direct, quantified comparison of modular versus consolidated, automated manufacturing and QC workflows, modeled across 200 and 2,000 batch scales. The analysis covers hands-on time, labor expenditure, cleanroom footprint and classification, QC operator burden, and manufacturing success rates, with findings that challenge common assumptions about where costs are actually generated and how much room exists to reduce them.

Access the full case study to see where the numbers land.